Blackrock, INC Schedule 13G passive stakes

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 7.7% beneficial ownership stake in CF Industries Holdings Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 7.4% of Cigna Corporation's common stock as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 14 to Schedule 13G, disclosing a beneficial ownership of 52,188,147 shares, representing 6.8% of Coterra Energy Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, reporting a 15.9% beneficial ownership stake in Caleres Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 3 to Schedule 13G, disclosing a 6.9% beneficial ownership stake in Capital City Bank Group Inc. as of March 31, 2025.

BlackRock, Inc. has filed a Schedule 13G, revealing a 6.4% passive ownership stake in CAVA Group, Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 9.1% beneficial ownership stake in Churchill Downs Inc. as of March 31, 2025, held for passive investment purposes.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing its beneficial ownership of 6.9% of Citigroup Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, confirming its beneficial ownership of 7.2% of Codexis Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 8.6% of Cognizant Technology Solutions Corporation's Class A Stock as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 3 to Schedule 13G, reporting a 9.4% beneficial ownership stake in Comfort Systems USA Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reaffirming its substantial 9.9% beneficial ownership stake in utility giant Consolidated Edison Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 9.9% beneficial ownership stake in Crown Holdings Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 8.3% of Dexcom Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.6% passive beneficial ownership stake in Dine Brands Global, Inc. as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 16 to its Schedule 13G, disclosing a 7.6% beneficial ownership stake in Discover Financial Services as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing its beneficial ownership of 8.0% of Cadence Design Systems Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 11 to Schedule 13G, reporting a beneficial ownership of 8.1% of Ducommun Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.8% beneficial ownership stake in Sierra Bancorp's common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 12.5% beneficial ownership stake in Skyworks Solutions Inc. as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 4 to its Schedule 13G, revealing a 7.7% passive beneficial ownership stake in Tactile Systems Technology Inc. as of March 31, 2025.

BlackRock, Inc. has filed an updated Schedule 13G, disclosing a 7.4% beneficial ownership stake in Tarsus Pharmaceuticals, Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.8% beneficial ownership stake in Teladoc Health Inc. as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 18 to its Schedule 13G, disclosing a 9.8% beneficial ownership stake in Trex Company Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.4% passive beneficial ownership stake in TScan Therapeutics, Inc. as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 3 to its Schedule 13G, reporting a 7.6% passive beneficial ownership stake in Turning Point Brands, Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.1% beneficial ownership stake in Ultragenyx Pharmaceutical Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.3% beneficial ownership stake in Valero Energy Corp as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.4% beneficial ownership stake in Voyager Therapeutics, Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 9.5% beneficial ownership stake in Welltower Inc. as of March 31, 2025.